Literature DB >> 8182712

Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents.

M M Goodman1, M P Kung, G W Kabalka, H F Kung, R Switzer.   

Abstract

Methods have been developed for the preparation of radioiodinated N-substituted 2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes. The syntheses, physical properties, radiolabeling, and characterization of the pharmacological properties of N-(3(Z)-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropane (12) and N-(3(E)-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropane (13) are described. 2 beta-Carbomethoxy-3 beta-(p-substituted-phenyl)tropanes are potent ligands for the dopamine transporter. The radioiodinated derivatives are of interest because of the high uptake and prolonged striatal retention that may result from specific binding to low-capacity, high-affinity, dopamine reuptake sites. Radioiodine was introduced into the 3Z and 3E-position of N-(3-iodopropen-1-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropane by iododemetalation of the corresponding 3-(tri-n-butylstannyl) derivatives. Competition binding data of various dopamine reuptake ligands with rat striatal tissue preparation for either [125I]-12 or [125I]-13 exhibited the following order of potency: E-13 > Z-12 > GBR 12909 >> mazindol >>> (-)-cocaine. Tissue distribution studies in rats showed that the E-13 was the best analogue. E-13 showed high striatal uptake (60 min, 1.23% dose/g; 120 min, 0.61% dose/g) and high striatal to cerebellum ratios (60 min, 15.9/1; 120 min, 16.5/1). These studies indicate that iodine-123-labeled E-13 is a potentially useful agent for imaging the dopamine reuptake sites by single-photon-emission computerized tomography.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182712     DOI: 10.1021/jm00036a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Whole-body biodistribution and radiation dosimetry estimates for the PET dopamine transporter probe 18F-FECNT in non-human primates.

Authors:  Dnyanesh N Tipre; Masahiro Fujita; Frederick T Chin; Nicholas Seneca; Douglas Vines; Jeih-San Liow; Victor W Pike; Robert B Innis
Journal:  Nucl Med Commun       Date:  2004-07       Impact factor: 1.690

2.  Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I.

Authors:  H Umesha Shetty; Sami S Zoghbi; Jeih-San Liow; Masanori Ichise; Jinsoo Hong; John L Musachio; Christer Halldin; Jurgen Seidel; Robert B Innis; Victor W Pike
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-10       Impact factor: 9.236

3.  Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.

Authors:  Aaron L Smith; Sara M Freeman; Jeffery S Stehouwer; Kiyoshi Inoue; Ronald J Voll; Larry J Young; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2012-02-25       Impact factor: 3.641

4.  Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Lauryn M Daniel; Ping Chen; Ronald J Voll; Larry Williams; Susan J Plott; John R Votaw; Michael J Owens; Leonard Howell; Mark M Goodman
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

Review 5.  Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors.

Authors:  Jaromir Myslivecek
Journal:  Life (Basel)       Date:  2022-04-19

6.  Radioiodination and Purification of [131I]β-CIT and [131I]FP-CIT with an Automated Radiosynthesizer.

Authors:  Elisabeth Plhak; Edith Gößnitzer; Reingard M Aigner; Herbert Kvaternik
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.